CONVENTIONAL THERAPEUTIC INTERVENTIONS FOR SARS-COV-2: A REVIEW
Nayanmoni Boruah, Hemanta Kumar Sharma, Sudarshana Borah*, Kamallochan Barman, Bhanita Das, Aditya Bora, Jayita Das and Pallab Kalita
ABSTRACT
The origin of the SARS-CoV-2, a β-coronavirus is not yet identified. The pandemic action of the virus has been intimidating peoples across the world. The spike proteins of the virus portray a crown-like configuration that binds with Angiotensin-converting enzyme 2 receptors via its six amino acids. The binding of the spike proteins and Angiotensin-converting enzyme 2 receptors results in the host transmission. We have investigated the different therapeutics for the management of COVID-19. A systematic literature survey has been carried out using research databases to understand the underlying mechanism and evaluate the drugs for prevention and treatment of COVID-19. The therapeutic interventions for COVID-19 can be categorized into two categories: virus-specific therapy and host-specific therapy. Researchers have been functioning on the repurposing of available pharmacological agents, including Antimalarials, Monoclonal antibodies, Convalescent plasma therapy, Protease inhibitors, Immunomodulators, Vaccines, Stem cell therapy as potential therapeutics to treat COVID-19. Potent immunomodulatory „Rasayana‟ plants possess phytoconstituents that may exhibit synergistic action could provide protection against SARS-CoV-2. Although, many existing drugs have been tried for the treatment of COVID-19, no drug alone or in combination has shown groundbreaking result. However, efforts are going on to develop the drug as well as vaccines. This development process is a time requiring process; until vaccines or new drugs become operational, repurposing of existing drugs is indispensable.
Keywords: Coronavirus, Angiotensin, Spike protein, Main protease, Rasayana, Vaccines.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
